Source: International Congress 2016 – Asthma points to ponder
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Petros Galanakis (Athens, Greece), Petros Galanakis, Mina Gaga, Fotios Psarros, Eleftherios Zervas, Eirini Mitsiki, Nikolaos Siafakas. Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study. Eur Respir J 2016; 48: Suppl. 60, 3380

Member's Comments

No comment yet.

Related content which might interest you: Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Real life experience of omalizumab on selected children with severe allergic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Patients with allergic and eosinophilic asthma in the German severe asthma registry Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks Source: Annual Congress 2013 –Treatment of asthma Year: 2013 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes Source: International Congress 2016 – Airway stenting and ablation Year: 2016 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Do atopy predict severity of asthma? Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 FeNO in children with asthma is related to inhaled corticosteroids adherence, not to asthma control Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 Longitudinal relationship between disease specific quality of life and asthma control in children Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 The impact of sublingual allergen-specific therapy on asthma control and quality of life Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016